

(b)(6);(b)(7)(C)

To: Sannerud, Christine A.
Cc: (b)(6);(b)(7)(C)
Subject: Procurement Quota Increase for Aurolife Pharma LLC (b)(4);(b)(7)(E)

Chris,

On Tuesday, July 7, 2015, ODGR received your request to review one (1) procurement quota increase application from **Aurolife Pharma LLC** (b)(4);(b)(7)(E) (including **Aurolife Pharma LLC Manufacturer** (b)(4);(b)(7)(E) and **Aurobindo Pharma USA, Inc. Distributor** (b)(4);(b)(7)(E) who distributes to (b)(4) customers to determine if there are any pending administrative/legal actions against these applicants and to advise ODEQ of the findings.

ODGR conducted reviews of (NADDIS, CSA, etc.), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION:

Aurolife Pharma LLC (b)(4);(b)(7)(E)
Aurolife Pharma LLC (Packager) (b)(4);(b)(7)(E)

Per consultation with the field offices, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from the **Aurolife Pharma LLC** (b)(4);(b)(7)(E) (including **Aurolife Pharma LLC Manufacturer** (b)(4);(b)(7)(E) and **Aurobindo Pharma USA, Inc. Distributor** (b)(4);(b)(7)(E)).

(b)(4);(b)(7)(E)

Based on the above findings, it is recommended that the increased amounts be reviewed to determine if they are warranted.

(b)(4);(b)(7)(E)

(b)(4);(b)(7)(E)

Based on this information, ODGR suggests that you proceed with the completion of the quota applications.

(b)(6);(b)(7)(C)

*Program Analyst/ODGR
Regulatory Unit*

(b)(6);(b)(7)(C)

(b)(6);(b)(7)(C)

@usdoj.gov


Memorandum



<p>Subject</p> <p>AUROLIFE PHARMA LLC (b)(4);(b)(7)(E) 2015 Procurement Quota Increase Request Hydrocodone (DFN: 630-08.2)</p>	<p>Date</p> <p>7/2/2015</p>
--	-----------------------------

To

Cathy Gallagher
Chief
Regulatory Section
Office of Diversion Control

From 
Christine A. Sannerud, Ph.D.
Chief
UN Reporting and Quota Section
Office of Diversion Control

Background:

As a result of the recent increase in the diversion and abuse of hydrocodone, ODQ requests that ODG review the attached application and determine the legitimacy of the applicant's customers. The application enclosed contains year to date sales (broken out by customer) for 2015 as provided by the registrant.

ODQ requests that ODG review and provide written comments to on the applicant's enclosed customer list. Specifically, ODQ requests information on whether the applicant's customers are currently under investigation or are the subject of an order to show cause or immediate suspension order. The sales made to such customers will be considered by ODQ when establishing/revising the applicant's quota allocation for hydrocodone.

Please feel free to contact me if I can provide further assistance in this matter.

**Drug Enforcement Administration
EXECUTIVE SECRETARIAT
CONTROL SHEET**

REG NO:	(b)(7)(E)	
AUTHOR:	Sannerud, Christine A Chief ODQ	DOC DATE: DATE 7/6/2015 RECEIVED:
LOCATION:	ODEQ	DATE DUE: 07/16/2015
TO:		DATE CLOSED:
SECURITY:	A-AES	CREATED BY: (b)(6);(b)(7)(C) 7/6/2015
DOC CATEGORIES:		MODIFIED BY: (b)(6);(b)(7)(C) 7/6/2015
DOC TYPE:		

ABSTRACT: Aurolife Pharma, LLC
(b)(4);(b)(7)(E)
2015 Procurement Quota Increase Request for hydrocodone.

SIGNATURE: ODGR/Regulatory Unit Response letter.

NOTES:

FYI - INFO COPIES:

FOLDER PRIORITY: High Priority

Assignments

Action	Action Officer	Delegator	Status	Date Assigned	Date Due	Closed	Security
Recommendation and Comments	ODG	(b)(6);(b)(7)(C)	Closed	7/6/2015	07/14/2015	7/6/2015	A-AES
Requested Activity:							
Reassign	(b)(6);(b)(7)(C)	(b)(6);(b)(7)(C)	Open	7/6/2015	07/20/2015		A-AES
Requested Activity:	Sending to ODGR (b)(6);(b)(7)(C) on 7/6/2015						
Return to Originating Office	(b)(6);(b)(7)(C)	(b)(6);(b)(7)(C)	Open	7/9/2015	07/16/2015		A-AES
Requested Activity:	Task completed by Staff Coordinators (b)(6);(b)(7)(C) 7-8-2015						

**Drug Enforcement Administration
EXECUTIVE SECRETARIAT
CONTROL SHEET**

REG NO:	(b)(7)(E)				
AUTHOR:	Sannerud, Christine A Chief ODG	DOC DATE:			
		DATE RECEIVED:	7/6/2015		
LOCATION:	ODFQ	DATE DUE:	07/16/2015		
TO:		DATE CLOSED:			
SECURITY:	A-ALS	CREATED BY:	(b)(6);(b)(7)(C)	7/6/2015	
DOC CATEGORIES:		MODIFIED BY:		7/6/2015	
DOC TYPE:					

ABSTRACT: Aurolife Pharma, LLC
(b)(4);(b)(7)(E)
2015 Procurement Quota Increase Request for hydrocodone.

SIGNATURE: ODGR/Regulatory Unit Response letter.

NOTES:
FYI - INFO
COPIES:
FOLDER PRIORITY: High Priority

Assignments

Action	Action Officer	Delegator	Status	Date Assigned	Date Due	Closed	Security
Recommendation and Comments	ODG	(b)(6);(b)(7)(C)	Closed	7/6/2015	07/14/2015	7/6/2015	A-AES
Requested Activity:							
Reassignment	(b)(6);(b)(7)(C)		Open	7/6/2015	07/20/2015		A-ALS
Requested Activity:	Sending to ODGR (b)(6);(b)(7)(C) on 7/6/2015						

(b)(6);(b)(7)(C)

SBF-CM
Folder Details

Folder ID: 139192

Reg No: (b)(7)(E)

Author: Sannerud, Christine A

Addressed To:

Location: ODEQ

Due: 07/16/2015

Received: 7/6/2015

Date Sent:

Response:

Security: A-AES

Abstract: Aurolife Pharma, LLC

(b)(4);(b)(7)(E)

2015 Procurement Quota Increase Request for hydrocodone.

Signature: From ODG Response letter.

Doc Categories:

Doc Types:

(b)(6);(b)(7)(C)

ODG

07/14/2015

Action: Recommendation and Comments

Requested Activity:

Response Notes:

7/6/2015 10:59:19 AM

1